Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
JR Molina, P Yang, SD Cassivi, SE Schild… - Mayo clinic …, 2008 - Elsevier
Lung cancer is the leading cause of cancer-related mortality not only in the United States but
also around the world. In North America, lung cancer has become more predominant among …
also around the world. In North America, lung cancer has become more predominant among …
Targeting apoptosis pathways in cancer therapy
IM Ghobrial, TE Witzig, AA Adjei - CA: a cancer journal for …, 2005 - Wiley Online Library
Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to
control cell proliferation or in response to DNA damage. The understanding of apoptosis has …
control cell proliferation or in response to DNA damage. The understanding of apoptosis has …
Blocking oncogenic Ras signaling for cancer therapy
AA Adjei - Journal of the National Cancer Institute, 2001 - academic.oup.com
The Ras gene product is a monomeric membrane-localized G protein of 21 kd that functions
as a molecular switch linking receptor and nonreceptor tyrosine kinase activation to …
as a molecular switch linking receptor and nonreceptor tyrosine kinase activation to …
[PDF][PDF] Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
RS Go, AA Adjei - Journal of Clinical Oncology, 1999 - Citeseer
Purpose: To review the pharmacodynamics, pharmacokinetics, toxicities, and relative
clinical activities of cisplatin and carboplatin. Through a search of the MEDLINE database …
clinical activities of cisplatin and carboplatin. Through a search of the MEDLINE database …
[PDF][PDF] Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart, AA Adjei, PM LoRusso… - Journal of clinical …, 2004 - Citeseer
Purpose This multicenter, open-label, phase II study was undertaken to assess the antitumor
activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase …
activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase …
[HTML][HTML] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY …
AA Adjei, RB Cohen, W Franklin, C Morris… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated
Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced …
Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced …
Small cell lung cancer
T Sher, GK Dy, AA Adjei - Mayo Clinic Proceedings, 2008 - Elsevier
Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the
cancer most commonly associated with various paraneoplastic syndromes, including the …
cancer most commonly associated with various paraneoplastic syndromes, including the …
Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor
Y Zhao, AA Adjei - The oncologist, 2015 - academic.oup.com
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …
human development and reproduction; however, aberrant regulation of angiogenesis is also …
[HTML][HTML] Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals
The views and recommendations made in this document do not represent the official
position of any publisher or professional medical society. This document has not been …
position of any publisher or professional medical society. This document has not been …
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003
P Yang, MS Allen, MC Aubry, JA Wampfler, RS Marks… - Chest, 2005 - Elsevier
Study objectives To improve the current understanding of the etiology and natural history of
primary lung cancer, we need to study the dynamic changes of clinical presentation and …
primary lung cancer, we need to study the dynamic changes of clinical presentation and …